A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma (Meeting abstract).

American Radium Society's 75th Annual Meeting. April 24-28, 1993, Aruba, p. 35, 1993.. Unique Identifier : AIDSLINE ICDB/94698273
Stelzer KJ; Griffin TW; Dept. of Radiation Oncology, Univ. of Washington Medical Center,; Seattle, WA

Abstract: The optimal dose of radiation in the treatment of AIDS-associated Kaposi's sarcoma (KS) has been controversial, based on previous nonrandomized retrospective studies. Seventy-one cutaneous AIDS-associated KS lesions were randomly assigned to one of three radiation dose regimens--800 cGy in one fraction, 2000 cGy in 10 fractions, and 4000 cGy in 20 fractions. Lesions were measured prior to and following treatment. Complete resolution of palpable tumor was considered a complete response (CR), regardless of residual purple pigmentation (RPP). Reduction in palpable tumor to less than 50% of pretreatment area was considered an objective response (OR). Less than 50% reduction in tumor size was considered a nonresponse (NR). Results: CR was higher (p=0.04) with 4000 cGy (83%) and 2000 cGy (79%) than with 800 cGy (50%). Absence of RPP was greater (p=0.005) with 4000 cGy (53%) than with 2000 cGy (8%) or 800 cGy (8%). Lesion failure was lower (p=0.03) with 4000 cGy (52%) than with 2000 cGy (67%) or 800 cGy (88%). Median time to failure was 43 weeks with 4000 cGy, 26 weeks with 2000 cGy, and 13 weeks with 800 cGy (p=0.003). Conclusions: Fractionated radiotherapy to higher total doses resulted in improved response and control of cutaneous KS. This dose-dependence should be considered in determining the optimal radiotherapeutic regimen for individual patients treated for epidemic KS.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Human Prospective Studies Radiotherapy Dosage Sarcoma, Kaposi's/ETIOLOGY/*RADIOTHERAPY Skin Neoplasms/ETIOLOGY/RADIOTHERAPY ABSTRACT RANDOMIZED CONTROLLED TRIAL CLINICAL TRIAL
940430
M9440912

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .